Terns Pharmaceuticals Receives Breakthrough Therapy Designation for TERN-701
Written by Emily J. Thompson, Senior Investment Analyst
Updated: Apr 27 2026
0mins
Terns Pharmaceuticals announced that the FDA granted breakthrough therapy designation to TERN-701, a novel, oral allosteric BCR::ABL1 inhibitor, for the treatment of adult patients with Ph+ CML in the chronic phase without the T315I mutation previously treated with two or more TKIs.
About the author
Emily J. Thompson
Emily J. Thompson, a Chartered Financial Analyst (CFA) with 12 years in investment research, graduated with honors from the Wharton School. Specializing in industrial and technology stocks, she provides in-depth analysis for Intellectia’s earnings and market brief reports.
